Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 2
1973 2
1974 3
1978 1
1981 3
1982 1
1983 1
1985 1
1986 1
1987 3
1989 1
1990 2
1991 1
1992 4
1993 3
1994 3
1995 5
1996 4
1997 5
1998 2
1999 1
2000 2
2001 5
2002 9
2003 3
2004 10
2005 7
2006 13
2007 11
2008 8
2009 10
2010 10
2011 11
2012 12
2013 7
2014 12
2015 19
2016 23
2017 14
2018 21
2019 20
2020 27
2021 20
2022 12
Text availability
Article attribute
Article type
Publication date

Search Results

300 results
Results by year
Filters applied: . Clear all
Page 1
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH. DiNardo CD, et al. Among authors: roberts aw. Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988. Blood. 2020. PMID: 31932844 Free PMC article.
Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A. Wei AH, et al. Among authors: roberts aw. Blood Rev. 2020 Nov;44:100672. doi: 10.1016/j.blre.2020.100672. Epub 2020 Feb 21. Blood Rev. 2020. PMID: 32204955 Free PMC article. Review.
Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.
Speir M, Nowell CJ, Chen AA, O'Donnell JA, Shamie IS, Lakin PR, D'Cruz AA, Braun RO, Babon JJ, Lewis RS, Bliss-Moreau M, Shlomovitz I, Wang S, Cengia LH, Stoica AI, Hakem R, Kelliher MA, O'Reilly LA, Patsiouras H, Lawlor KE, Weller E, Lewis NE, Roberts AW, Gerlic M, Croker BA. Speir M, et al. Among authors: roberts aw. Nat Immunol. 2020 Jan;21(1):54-64. doi: 10.1038/s41590-019-0550-7. Epub 2019 Dec 9. Nat Immunol. 2020. PMID: 31819256 Free PMC article.
Therapeutic development and current uses of BCL-2 inhibition.
Roberts AW. Roberts AW. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):1-9. doi: 10.1182/hematology.2020000154. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275682 Free PMC article. Review.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. Souers AJ, et al. Among authors: roberts aw. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6. Nat Med. 2013. PMID: 23291630
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. Merino D, et al. Among authors: roberts aw. Cancer Cell. 2018 Dec 10;34(6):879-891. doi: 10.1016/j.ccell.2018.11.004. Cancer Cell. 2018. PMID: 30537511 Free article. Review.
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Tam CS, et al. Among authors: roberts aw. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Free article. Clinical Trial.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Roberts AW, et al. N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6. N Engl J Med. 2016. PMID: 26639348 Free PMC article. Clinical Trial.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Tam CS, et al. Among authors: roberts aw. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. Blood. 2019. PMID: 31340982 Free PMC article. Clinical Trial.
300 results